# GCHA Quality Diversity Audit Report

## Prepared by: London PMO Quality Director | Date: 2026-05-15
## Document Status: OFFICIAL — Ethical Response to Silent Bug Crisis

---

## ⚠ CLASSIFICATION: PATIENT SAFETY INCIDENT

---

## Section 1: The Failure — Defining the Silent Bug

### What Is a "Silent Bug"?

A Silent Bug is a defect that is invisible during standard testing
because the testing conditions did not cover the affected scenario.
It passes every test — because no one tested the right case.

### The GCHA Silent Bug — ISO 25010 Analysis

**Bug Description:**
The GCHA AI Diagnostic Engine achieves 98% accuracy when predicting
health risks for patients in European hospital datasets. However, when
tested against patient data from Cairo and Dubai hospitals, accuracy
drops to 70% — a 28-percentage-point degradation for Middle Eastern
and North African patient demographics.

**Root Cause:**
The AI was trained exclusively on European patient biometric datasets.
It was never exposed to the physiological variation patterns present
in Middle Eastern populations. This is a Training Data Bias failure —
not a code error.

**ISO 25010 Pillars Failed:**

| Pillar | Failure Description |
|--------|---------------------|
| **Functional Suitability** | The system does NOT meet the clinical needs of 30%+ of the patient population it is deployed to serve. |
| **Reliability** | The system cannot be described as reliable when accuracy degrades by 28 percentage points across demographic groups. |

**Phase Containment Analysis:**
This failure originated in the **Requirements Phase** — London failed
to specify "the AI must achieve ≥ 95% accuracy across all patient
demographics served by GCHA hospitals." By the time it was discovered
in System Testing, it had leaked through Design and 6 months of model
training — making it a 1:1,000 cost multiplication event.

**DRE Impact:**
The Silent Bug was caught by Cairo Testing (internal) — this is an
Appraisal Cost success. However, had it not been caught before
launch, it would have become an External Failure: 30% of patients
in Cairo and Dubai hospitals would have received clinically compromised
AI predictions from Day 1 of rollout.

---

## Section 2: The Decision — Halting the Rollout

### Decision: ROLLOUT HALTED

**Date of Decision:** 2026-05-15
**Authority:** London PMO Quality Director, escalated to GlobalCare CEO

**ACM/IEEE PUBLIC Principle Invocation:**
This decision is made in accordance with the ACM/IEEE Code of Ethics,
Principle 1 — PUBLIC:

> "Software engineers shall act consistently with the public interest."

Proceeding with a rollout that knowingly delivers 30% reduced
diagnostic accuracy to Cairo and Dubai hospital patients is a direct
violation of this principle. Patient safety is non-negotiable and
supersedes the rollout timeline, the Board's financial targets,
and the project team's schedule pressure.

**New Quality Gate — Mandatory Before Any Hospital Deployment:**
The GCHA AI Engine cannot be deployed to ANY hospital until the
following criterion is met:

> "The AI Diagnostic Engine must achieve ≥ 95% accuracy across
>  ALL patient demographic datasets: European, Middle Eastern,
>  North African, and South Asian populations."

This gate is non-negotiable and cannot be waived by any stakeholder.

---

## Section 3: The Correction — New Prevention Cost Investments

**Total Additional Investment Required:** ~$200,000
(vs. $50,000,000 in potential External Failure costs — ROI: 250:1)

### Prevention Investment 1: Diverse Dataset Purchase

**Cost:** ~$80,000
**Description:** License access to anonymized patient biometric datasets
from Middle Eastern and North African healthcare providers. Minimum
requirement: 500,000 patient records representing MENA demographics.
**Responsible Site:** Berlin AI Team
**Timeline:** 6 weeks to acquire, pre-process, and integrate

### Prevention Investment 2: Regional Bias Training Program

**Cost:** ~$50,000
**Description:** Mandatory training for the Berlin AI team on algorithmic
bias detection, demographic fairness testing, and diversity-aware model
evaluation. Delivered by an external AI Ethics specialist.
**Responsible Site:** Berlin (all AI team members) + London PMO oversight
**Timeline:** 2-week intensive program

### Prevention Investment 3: Demographic Accuracy Validation Suite

**Cost:** ~$70,000
**Description:** Commission the Cairo Testing Team to build and maintain
a permanent test suite that validates AI accuracy across all demographic
groups after every model update. This suite becomes part of every
future Quality Gate for the AI module.
**Responsible Site:** Cairo Testing Team
**Timeline:** 4 weeks to build, then permanent maintenance

### Cost of Quality Justification

| Action | Cost | Prevention Value |
|--------|------|-----------------|
| Diverse Dataset Purchase | $80,000 | Eliminates Training Data Bias |
| Regional Bias Training | $50,000 | Prevents future demographic blind spots |
| Demographic Test Suite | $70,000 | Permanent Appraisal gate for all future releases |
| **Total Prevention** | **$200,000** | **Prevents $50M+ External Failure** |

**ROI Calculation:**

| | |
|--|--|
| External Failure Prevented | $50,000,000 |
| Prevention Investment | $200,000 |
| Net Savings | $49,800,000 |
| ROI Ratio | 250:1 |

---

*This document is an official quality management record.
It must be retained for a minimum of 7 years per GDPR Article 30.
Prepared by: PMO Team 01 | Reviewed by: GlobalCare CEO | Date: 2026-05-15*
